REQUEST A DEMO
总计
USD $0.00
搜索更多公司

Ys Biopharma Co. Ltd. (中国)

主营业务: 医药制剂制造
全名: Ys Biopharma Co. Ltd. 公司更新日期: 2024.07.27
购买我们的报告为这家公司 USD 29.95 最近财务数据:2024 可有的: 英语 & 中文 下载示例的报告

The Company is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics.
History
2020 The Company was incorporated under the laws of Cayman Islands as an exempted company with limited liability in November 2020. The history of YS Group can be traced back to 2002 when Mr. Yi Zhang, its founder and controlling shareholder started the vaccine business in the PRC, and has expanded its international business operation in the United States and Singapore since 2009.
2022 On September 29, 2022, Summit, YS Biopharma, Merger Sub I, and Merger Sub II entered into the Business Combination Agreement, which provides for (i) the merger of Merger Sub I with and into Summit, with Summit surviving the First Merger as the surviving entity and becoming a wholly-owned subsidiary of YS Biopharma, and (ii) the merger of the Surviving Entity with and into Merger Sub II, with Merger Sub II surviving the Second Merger as the surviving company and remaining as the wholly-owned subsidiary of YS Biopharma. As a result of and upon consummation of the Business Combination, the shareholders of Summit will become shareholders of YS Biopharma, and YS Biopharma will become a public company with its ordinary shares and warrants listed on the Nasdaq. Capitalized terms in this summary of the Business Combination Proposal not otherwise defined in this proxy statement/prospectus shall have the meanings ascribed to them in the Business Combination Agreement.
Prior to the First Merger Effective Time, the Company will be renamed as YS Biopharma Co., Ltd.
Stock Exchange Listing of YS Biopharma Ordinary Shares and YS Biopharma Warrants:
The YS Biopharma Ordinary Shares and YS Biopharma Warrants issuable pursuant to the Business Combination Agreement to be approved for listing on Nasdaq under the symbols “YS”and “YSBPW”, respectively, subject to official notice of issuance.

总部
Building No. 2, 38 Yongda Road Daxing Biomedical Industry Park, Daxing District
北京; 北京;

联系方式: 购买Ys Biopharma Co. Ltd.报告以查看信息。

网站: http://www.yishengbio.com.

基本信息
员工总数:
购买Ys Biopharma Co. Ltd.报告以查看信息。
流通股:
购买Ys Biopharma Co. Ltd.报告以查看信息。
财务审计师:
购买Ys Biopharma Co. Ltd.报告以查看信息。
成立日期:
2020
主要管理人员
购买此报告以查看信息。
President
购买此报告以查看信息。
Chief Executive Officer
购买此报告以查看信息。
Chief Executive Officer
购买此报告以查看信息。
Director/Member of the Board
购买此报告以查看信息。
Director/Member of the Board
公司业绩
图表中的财务价值可在之后获得Ys Biopharma Co. Ltd.报告购买。
寻找的不仅仅是一个公司的报告吗?

EMIS公司简介是一个更大的信息服务的一部分,它结合了公司,行业和国家数据和分析在超过125个新兴市场.

请求EMIS服务的演示
主要财务重点
年增长百分比对于以当地货币近两年CNY。绝对财务数据包含在购买报告中。
销售净额
-16.56%
营业收入总计
-16.56%
营业利润
-265.88%
EBITDA
-139.77%
净利润(亏损)
-52.91%
总资产
-12.02%
权益总额
-19.66%
经营利润率
-55.91%
销售收益率
-34.34%
股本收益率
-35.16%
负债股权比率
4.42%
速动比率
-0.42%
现金比率
-0.25%

查看更多信息, 申请试用

购买这家公司报告
需要定期访问公司,行业或国家/地区的信息吗?